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INTRODUCTION
The complement system plays an important role in the initia-
tion of acute and chronic inflammation. Activation of the corn-
plement cascade may lead to tissue damage by chemotactic attrac-
tion and changes in the activity of polymorphonuclear leukocytes
which may release damaging proteolytic enzymes, degranulation of
mast cells and complement-mediated lysis of tissue cells. In
addition, complement activation may stimulate osteoclastic bone
resorption, the production of lymphokines and increased differen-
tiation of B-lymphocytes. Destruction of connective tissue and
bone are prominet, features in periodontal disease and emphasi.ze
the potential importance of complement activation in this disease
process.
Evidence exists that complement activation occurs in perio-
dontal disease. Native C3 and C4 are reduced in gingival fluid
compared to serum in patients with severe periodontal disease
(Schenkein and Genco 1977a, Attstrom et al. 1975). Complement
activation may occur consequent to antigen-antibody reaction or
by several alternative means. Cleavage of C3 in gingival fluid
by the alternative and/or classical pathways or by direct enzyma-
tic conversion is suggested by the presence of the conversion
product C3c (Attstrom et al. 1975, Schenkein and Genco 1977a) and
C3d (Schenkein and Genco 1977b) in gingival fluid.
These previous studies indicate that complement cleavage
occurs in very severe periodontal disease. These investigations,
however, were conducted only in patients with severe periodon-
titis. Due to the small amounts of gingival fluid obtainable
from mildly inflamed tissues, no longitudinal studies of comple-
ment activation have been reported. The new measurement tech-
nique utilizing filter paper strips presented in this manuscript
allows measurement of complement cleavage by crossed-immunoelec-
trophoresis from gingival fluid samples taken from areas of
minimal inflammation. In addition, modification of this tech-
nique by the Master’s candidate allows the simultaneous measure-
ment by of C3, C4, B and their cleavage products from a gingival
fluid sample as small as 0.2 ul. This technique allows longitu-
dinal studies of complement cleavage in periodontal disease.
The human complement system is a principal defense mechanism
which acts to protect the host from foreign substances. However,
activation of the complement system may also lead to damage of
host tissue and exacerbation of the inflammatory response. The
extensive biologic activities of complement result primarily from
the cleavage products resulting from activation of the complement
cascade. The complement system consists of a series of proteins
which can be divided into three major pathways: the classical,
the alternative activating, and the terminal pathways.
Classical Pathwa
The classical pathway, activated primarily by antigen-
antibody complexes (Hyslop et al. 1970), consists of a cascade of
alternating proteolytic cleavage and protein-binding reactions
with important host defense consequences. Thus, its major func-
tion is to provide an amplification mechanism consequent to the
interaction of antigen with specific antibody. Other substances,
such as C-reactive protein, an acute phase serum protein, also
cause activation of the classical pathway (Siegel et al. 1976,
Volanakis and Kaplan 1974).
The recognition unit of the classical pathway, Cl, is a
trimolecular complex consisting of Clq, Clr, and Cls (Lepow et
al. 1963). Clq, which consists of six peripheral subunits con-
nected by fibrillar strands to a central core (Knobel et al.
1975, Shelton et al. 1972), recognizes the Fc portion of immuno-
logically complexed IgG (IgGl, IgG2, IgG3 or IgM antibody
(Augener et al. 1971). At least two IgG molecules in close
proximity or one IgM pentamer are essential for the binding of
Clq (Colten et al. 1968). In the presence of calcium ions, this
binding is thought to induce a change in the conformation of Clr
(M011er-Eberhard 1977), causing a self-cleavage reaction that
activates Clr (Naff and Ratnoff 1968). The activated Clr then
cleaves a peptide bond in Cls to reveal its enzymatically active
serine esteratic site.
The natural substrates of Cls in serum are C4 and C2, the
next two components in the classical cascade (Mller-Eberhard and
Lepow 1965). Cleavage of C4 and C2 by Cls leads to-the formation
of the short-li.ved activated proteins, C4b and C2a. Cl first
cleaves C4 into C4b and C4a with C4b attaching to the immune
complex (Law et al. 1980). Cls then cleaves C2 into the larger
C2a and the smaller C2b fragment (Kerr 1980) with C2a binding to
the attached C4b. This complex, C4b, C2a, formed in the presence
of Mg++, functions enzymatically as the classical pathway C3
convertase which cleaves C3 into two fragments, C3a and the
larger C3b.
The classical complement system is controlled by a variety
of naturally occurring biochemical regulators present in serum.
Cl activity is balanced by the glycoprotein Cl inhibitor (Cl INH)
(Ratnoff and Lepow 1957), which forms a stoichiometric complex
with the active sites of both Clr and Cls. This abrogates their
enzymatic activity and causes the dissociation of Cir and Cls
from antigen-antibody-Cl aggregates (Sim and Reboul 1981). Clq
inhibitor has recently been described as physically binding to
Clq and blocking its activity (Ghebrehiwet 1981).
C4 is inactivated by two plasma proteins acting together.
C4 Binding Protein (C4BP) acts as a cofactor for the degradation
of C4b by the enzyme I (C3b inactivator, Fujita et al. 1978).
When bound or soluble C4b is complexed with C4BP, it is subject
to cleavage by I (Gigli et al. 1979, Nagasawa et al. 1980, Press
and Gagnon 1981). Serum proteases act to release C4c, inactiva-
ting C4b. In addition, the C4b,C2a complex is inherently un-
stable and dissociates rapidly.
Alternative Activating Pathway
The alternative activating pathway of complement was postu-
lated in 1954 by Louis Pillemer based on observations of serum
proteins active in early host defenses against bacteria and
viruses in the absence of antibodies (Pillemer et al. 1954).
Specific immunity is therefore not required for the activity of
the alternative activating pathway (G6tze and Mller-Eberhard
1976). The initiation of the enzyme cascade by certain micro-
organisms and mammalian cells is dependent on the chemical com-
position of their cell surface rather than on the formation of
immune complexes. The activators of the alternative activating
pathway of human complement include a variety of microbial poly-
saccharides such as lipopolysaccharides from Gram negative bac-
teria (Marcus et al. 1971), teichoic acid from pneumococci
(Winkelstein and Tomasz 1978), and zymosan from yeast (Pillemer
et al. 1954). In addition, this complement pathway has been
shown to inactivate many viruses (Hirsch et al. 1980, Mills et
al. 1979, Welsh 1977) and to kill a number of helminthic and
protozoan parasites (Santoro et al. 1979) in the absence of
antibody. However, antibody-dependent activation of the alterna-
tire activating pathway has been described for immune aggregates
of certain IgG and IgA subclasses, and with aggregates containing
IgD and Ig,E (Reid 1983). Also, certain immune complexes have
been shown,to initiate the alternative activating pathway .in the
absence of ’classical pathway components Cl and C4 (Edwards et al.
1980).
The initiating event in the alternative activating pathway
of complement involves the formation of a priming C3 convertase,
C3,Bb formed by the interaction of C3 (which has undergone a
spontaneous hydrolysis of a thioester bond) with B to form C3,B
which is then cleaved by the enzyme D in the presence of Mg++ to
yield C3,Bb (Fearon and Austen 1975). This occurs continually at
a slow rate in plasma and generates small amounts of C3b by the
enzymatic action of C3,Bb on C3. Initiation of the amplification
loop of the alternative activating pathway is determined by the
attachment of C3b to an activating surface.
In the presence of an activating surface, C3b covalently
attaches to it and is therefore less susceptible to the regula-
tory proteins. B then binds to C3b in the presence of Mg ++. D
(proactivator convertase), a serine esterase present in serum
only in its active form with no known specific inhibitor, then
cleaves the bound B into Ba, which is released, and the larger Bb
(Lesavre and Mller-Eberhard 1978). Bb forms a labile bimolecu-
lar complex with C3b, C3b,Bb. P (properdin) is adsorbed to the
C3b,Bb complex from the serum and results in stabilization of
that complex (Medicus et al. 1980), with a five-fold increase in
its i__n yitro half-life (Fearon and Austen 1975). The formation
of C3b,Bb, the C3 or "amplification" convertase, is the major
step in the. activation of the alternative activating pathway. It
acts to cleave C3 into C3a and C3b. Bound C3b may then recruit
the alternative activating pathway components, B, D, and P to
assemble more C3b,Bb complexes, creating many more molecules of
C3 convertase. The C3b-dependent C3 convertase is also capable
of amplifying C3 cleavage initiated by the classical pathway.
The protein B contains the proteolytic site for C3 cleavage.
This activity is partially expressed in the C3,Bb complex (ini-
tiation loop) and is fully exposed in the C3b, Bb complex (activa-
tion loop, Fearon et al. 1973, Gtze and Mller-Eberhard 1976,
Medicus et al. 1976). This accounts for the differences in the
activity of the two alternative activating pathway C3 conver-
tases: one resulting in continuous, low-grade production of C3b,
and the other incorporating the priming C3b with subsequent
amplified cleavage of C3.
In the absence of an activating surface, the regulatory
proteins dominate and no amplification is achieved. The C3b, B
and C3b,Bb complexes are dissociated by H (beta-IH), a serum
glycoprotein that competes for the B binding site on bound or
free C3b (Fearon and Austen 1977). I (C3b inactivator), an
endopeptidase, then cleaves the C3b complexed with H to form
inactive iC3b (Law et al. 1979, Mller-Eberhard and Schreiber
1980, Pangburn et al. 1977), destroying the hemolytic and immune
adherence reactivity of C3b. iC3b is susceptible to degradation
by other proteases (trypsin, plasmin and leukocyte elastase
(Johnson et al.. 1976, Taylor et al. 1977)), generating C3c (in
fluid phase) and C3d (which remains bound). C3c may then be
cleaved to form C3e.
The competition between B and H for C3b determines whether
or not the alternative activating pathway is triggered (Fearon
and Austen 1977, Kazatchkine et al. 1979). This is decided by
the presence or absence of certain cell membrane constituents
(activators of the alternative pathway) which protect C3b from
inactivation and block the active dissociation of P,C3b,Bb by the
regulatory proteins. For example, C3b with no activator surface
binds H with almost one hundred-fold greater affinity than it
binds B (Kazatchkine et al. 1979). Competition between B and H
for bound C3b is influenced by the amount of membrane sialic
acid, heparin, and C3 receptor protein.
In addition, the appropriate activating surface must be
close enough to the C3b molecule for attachment to occur before
the metastable binding site on C3b decays. The C3b receptor of
human erythrocytes, polymorphonuclear leukocytes (PMNs), mono-
cytes, and B-lymphocytes strongly binds to C3b and exhibits H-
like activity. These receptors, therefore, regulate the alterna-
tive activating pathway by inhibiting formation of the C3 ampli-
fication convertase (Fearon 1979).
Terminal Pathway
The C3 convertases of both the classical and alternative
activating pathways of complement become C5 cOnvertases by bin-
ding C3b. This binding exposes active sites on C2a and Bb,
respectively, allowing C4b,C2a,C3b (Cooper and M011er-Eberhard
1975) and activator-bound C3b,Bb,C3b staLuilizeuA Dy co act
identically to split one bond in the alpha-chain of C5. This
last proteolytic step of the complement pathways yields the
smaller C5a (Hugli 1975) which is released and C5b which binds to
the alternative pathway activator or to the immune complex. The
membrane attack complex which follows is a rapid non-enzymatic
process common to both pathways. C5b combines with C6 (Yamamoto
and Gewurz 1978) and C7 (Podack et al. 1978) to form the trimo-
lecular complex C5b,C6,C7 which intimately attaches to target-
cell lipid membrane via the generation of hydrophobic forces
(Monahan and Sodetz 1981). C8 then binds to the attached complex
and forms a structural pore through the lipid bilayer of the
membrane permitting bidirectional ion and water passage. C9
-I0-
combines with the C5b,C6,C7,C8 complex and acts as an acceler-
ating factor leading to osmotic lysis and death of the target
cell. Cell lysis is characterized by distinct 100A circular
lesions. This final membrane attack complex is stable and has a
molecular weight of 1,000,000 daltons (Kolb and Mller-Eberhard
1975).
The regulators of this terminal pathway act by inserting
into the membrane attack complex as it forms, preventing the
attachment of the complex to the target cell membrane. These
regulators include low density lipoproteins (Lint et al. 1977),
Anti-thrombin III, and the $ protein of normal serum (Podack et
al. 1978b).
Sensitivity of bacteria to the lytic action of the membrane
attack complex appears to be related to the "-’LL,+/-UI u- ne-’- cell
wall. Most gram-negative organisms can be killed by antibody and
complement, but most gram-positive organisms are resistant.
Biologi_c Activities o__f Complement
The activation of the complement cascade induces many of the
phenomena characteristic of inflammation. This response contri-
butes to host defenses by protecting against foreign substances,
but may also be responsible for damage to host tissues. Most of
the biologic activities result from the release of limited pro-
teolytic cleavage products formed by the complement cascade.
Others are caused by’ the binding of complement cleavage products
-II-
to other cells, such as macrophages, PMNs, lymphocytes, erythro-
cytes, and platelets.
Effect on _the vasculatur_e. Increased vascular permeability
re.sults from two potent stimulators of inflammation, C3a (Hugli
1975, Hugli and M011er-Eberhard 1978) and C5a (Gerard and Hugli
1979, Gerard et al. 1981). These low molecular weight anaphyla-
toxins (generated by both the classical and alternative activa-
ting pathways of complement) cause degranulation and release of
histamine from human mast cells and basophils by non-lytic mech-
anisms, resulting ultimately in smooth muscle contraction (Gerard
et al. 1980) and increased vascular permeability. In fact, C3a
and C5a elicit an immediate edema and erythema reaction when
injected into human skin even at extremely low concentrations.
C4a has also been shown to exhibit anaphylatoxic activity (Gorski
et al. 1979). The vascular permeability effects of C3a, C4a, and
C5a are controlled by anaphylatoxin inactivator, a carboxypepti-
dase present in human serum that removes the carboxy-terminal
arginine residue (Bokish and Mler-Eberhard 1970). Changes in
vascular permeability (a kinin-like activity) also result from a
vasoactive peptide cleavage fragment of C2 (Klemperer et al.
1969, Becker et al. 1974).
Effect ol! granulocYtes. The accumulation of leukocytes is
characteristic of inflammation and is a prime defensive mechanism
of the host. C5a, a chemotactic factor produced by proteolytic
cleavage of C5, stimulates directed movement of neutrophils,
basophils, eosinophils, and monocytes (Ward and Newman 1969).
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C3b,Bb and Ba (Hadding et al. 1978), formed by the alternative
activating pathway, have been shown to be chemotactic for neutro-
phils (Takahashi et al. 1980). In addition, the decay product of
C5b,C6,C7 exhibits chemotactic activity in (Ward et al.
1966). Complement-derived chemotactic factors have been shown to
have potent in v_iy_Q activity. They have been isolated from
inflamed tissues and local injection of these factors causes an
accumulation of leukocytes (Ward and Becker 1977). A factor
present in serum is able to destroy the complement-derived
chemotactic activity (Kreutzer et al. 1979). The chemotactic
activity of C3a is controversial (Damerau 1978, Rother 1972).
A systemic leukocyte mobilizing effect has been shown for
C3e, leading to leukocytosis by stimulating PMN release from bone
marrow (Ghebrehiwet and Mller-Eberhard 1979). C3e, therefore,
increases the pool of responding cells in inflammation.
In addition to the chemoattraction of leukocytes to sites of
complement activation, several complement cleavage products lead
to changes in the activity and responsiveness of leukocytes. C3b
has been shown to increase neutrophil oxidative metabolism
(Goldstein et al. 1976) and also to permit subthreshold amounts
of immunoglobulin to cause lysosomal enzyme release. A cleavage
fragment of C5 causes aggregation of granulocytes (O’Flaherty et
al. 1977a), reflected by an increase in their adhesiveness
(Craddock et al. 1977), which may serve a role in margination, an
early inflammatory response (O’Flaherty et al. 1977b). C5a has
been shown in _v to stimulate the secretion of lysosomal
enzymes from neutrophils (Becker et al. 1974, Goldstein and
Weissman 1974).
Several complement components are also active in promoting
immune adherence and opsonization. C3b-coated target cells or
immune complexes have been shown to bind to certain cells which
possess specialized membrane receptors for C3b. PMNs, macro-
phages, monocytes, eosinophils, and lymphocytes all possess
stable surface receptors for C3b. This immune adherence through
the C3b receptors facilitates the involvement of these cells in
the inflammatory response (Gigli and Nelson 1968). When opsonized
by C3b, one hundred times more bacteria bind to a neutrophil
membrane than when bacteria are opsonized by IgG alone (Menzel et
al. 1978). Although binding appears to be strongly promoted, C3b
alone does not seem to induce phagocytosis. However, a synergy
exists between IgG and C3b in IgG-mediated phagoctosis (Fearon
1979). C4b also promotes the immune adherence phenomenon (Cooper
1969) and CSb may act to increase the phagocytosis of C3b-opson-
ized bacte r i a.
Effec.t o_/! monuclear cells. Bb activates macrophages,
causing spreading of peripheral monocytes (Gtze et al. 1979) and
migration inhibition. In addition, C3b has been shown to cause
IgG-independent lysosomal enzyme secretion by cultured guinea pig
and murine peritoneal macrophages (Schorlemmer and Allison 1976).
Evidence exists that activated mouse macrophages bind and ingest
C3b-coated particles in the absence of IgG (Bianco et al. 1976).
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Macrophages also have iC3b receptors, thought to promote attach-
ment but not phagocytosis. The macrophage C3b receptors may
serve a critical role in presentation of antigen to antibody-
producing cells. B-lymphocytes (Ross et al. 1973), peripheral
blood monocytes (Ehlenberger and Nussenweig 1975), and macro-
phages (Reynolds et al. 1975) bear receptors for C3d which may be
involved in immune adherence.
Complement cleavage products from both complement pathways
influence lymphocyte activity. The adherence reaction of C3b-
bearing particles stimulates the secretion of chemotactic lympho-
kines by B-lymphocytes (Sandberg et al. 1975), and promotes the
development of B-cells into memory cells (Klaus and Humphrey
1977) and antibody-secreting cells (Lewis et al. 1977). C3c and
C3d have been recently shown to inhibit T-lymphocyte prolifera-
tion by antigen (Schenkein and Genco 1979).
Indirect evidence exists to suggest that the differentiation
of lymphocytes is affected by C3b. /d! 3, the depletion of C3
prevents the development of the primary response to T-dependent
antigens, thought to be mediated through C3d receptors present on
some B-lymphocytes (Pepys 1974).
Q_ effect..s. Complement activation also leads to irrever-
sible damage to biological membranes through the common terminal
pathway. The membrane attack complex (C5b,C6,C7,C8,C9) does not
involve specific receptor binding and leads to uptake of salt and
water by the target cell with ultimate lysis. This occurs in
target bacterial or tumor cells, but can also cause damage-to
-15-
host tissues by the innocent bystander phenomenon or through
autoimmune mechanisms.
Complement-dependent prostaglandin-mediated bone resorption
has been shown when the bone tissue has been incubated with anti-
serum or heterologous serum (Raisz et al. 1974). In addition, it
has recently been shown that C3b, iC3b and C3c induce human
mononuclear phagocytes to synthesize and secrete prostaglandin
(Rutherford and Schenkein 1983).
C3b may inhibit cross-linking and lattice formation of
immune complexes, resulting in the solubilization of large immune
complexes. These solubilized complexes cad neither bind cells
nor activate complement (Takahashi et al. 1980).
Other complement products have a variety of effects inclu-
ding: C5 split products may trigger the extrinsic clotting path-
way (Muhlfelder et al. 1979), C4b may be important in virus
neutralization (Daniels et al. 1969).
Complement and Inflammatory Disease
Activation of the complement cascade results in a variety of
biologic effects. These include: i) irreversible damage to bio-
logic membranes, 2) deposition of molecules on the surface of
particles to opsonize and to promote clearance, and 3) formation
of potent mediators of the inflammatory response. These activi-
ties, although beneficial to the host, also possess an inherent
potential for coincidental damage. The complement system has,
therefore, been implicated in a variety of inflammatory diseases.
-16-
Direct cytotoxic injury involves antibody reacting directly
with a cell and activating the complement enzyme cascade.
Inflammatory mediators are released and the cells are damaged.
Autoimmune hemolytic anemia results from this process with the
development of antibodies to erythrocyte antigens. Nephrotoxic
nephritis is also thought to result from complement-mediated
cytotoxic reactions.
Circulating immune complexes induce tissue injury through
activation of the complement system. These antigen-antibody com-
plexes deposit in tissues that have no antigenic relationship to
the antibody, such as renal glomeruli or vascular endothelium and
initiate complement cleavage and the consequent inflammatory
sequelae. In instances of antibody excess, Arthus-type vascu-
litis reactions result. Farmer’s lung (hypersensitivity pneu-
monitis) is an example of this phenomenon, with inhaled antigens
combining with antibodies in the alveoli, activating complement,
and inducing an inflammatory response. Antigen excess results in
"serum sickness" type reactions with immune complex deposition
and complement activation culminating in glomerulonephritis,
arthritis, and vasculitis. This occurs following exposure to
sensitizing antigens in drugs or foreign serum. The local ization
of the immune complexes and inflammatory sequelae depend on the
chemical and physical nature of the antigen-antibody complexes in
addition to the properties of the target tissue (Cochrane 1971).
Immune complexes of IgGI, IgG2, IgG3, or IgM are known to acti-
vate the classical pathway of complement. However, in immune
-17-
complex disease, the alternative pathway of complement is thought
to participate at least through its amplification loop. C3b
production by the classical pathway leads to alternative pathway
C3 convertase generation.
_
vivo, C3, P and H deposits are
found in addition to immune complexes in the glomeruli (Wyatt et
al. 1 97 9).
Autoantibodies formed against soluble antigens to which they
are continually exposed, give rise to a constant supply of immune
complexes and to lesions similar to serum sickness. In Systemic
Lupus Erythematosis (SLE) with renal dysfunction, complexes of
DNA and other nuclear antigens with IgG and complement have been
visualized in the glomeruli of patients by using immunofluores-
cent techniques (Koffler et al. 1971). Electron microscopic
studies have confirmed the presence of "lumpy-bumpy" immune corn-
plex deposits on the epithelial side of the glomerular basement
membrane (Koffler.et al. 1971). Further evidence exists to
solidly link complement cleavage with SLE. The active phase of
SLE (increased clinical severity of the disease) has been asso-
ciated with a drop in total serum complement levels attributed to
cascade activation by immune complexes in the circulation and in
the kidneys (Williams and Law 1958, Ellis and Felix-Davies 1959).
In longitudinal observations, Schur and Sandson (1968) observed
decreased complement levels in advance of clinical exacerbation.
In fact, clinical symptoms, immune complex concentrations, and
complement levels appear to be strongly associated. Patients
with persistently depressed C3 had more symptoms of nephritis
-18-
(Stastny and Ziff 1968), associated with cold-insoluble immune
complexes (Stastny and Z iff 1969) and circulating antibodies to
nuclear antigens (Tojo and Friou 1968, Townes et al. 1963) which
activate complement. Therefore, it is hypothesized that circula-
ting immune complexes deposit beneath the glomerular basement
membrane, activate complement and incite an inflammatory
response. This process may be compounded by the phenomenon of
defective immune complex solubilizing capacity observed in sera
from patients with active SLE (Sakurai et al. 1982).
The most consistently depressed complement component in SLE
serum is C4 (Perrin et al. 1973). However, elevated serum fennels
of Ba and reduced levels of B have been observed during periods
of intense classical pathway activation (Hunsicker et al. 1972,
Perrin et al. 1975). These alternative pathway cleavage products
have been seen chiefly in cases where the classical pathway has
been activated (Perrin et al. 1973, Hunnsicker et al. 1972);
serum B depressions have been observed in sera with already
depressed C4 (Perrin et al. 1973), suggesting the primary role of
the classical pathway and an amplification role for the alterna-
tire pathway. Similar mechanisms have been implicated in a
variety of diseases such as polyarteritis nodosa with inflam-
matory lesions in the blood vessel walls.
Complement serum depressions have been associated with other
systemic rheumatic diseases including mixed IgG-IgM cryoglob-
ulinemia (Riethmuller et al. 1966, Wilson et al 1977), Walden-
strom’s macroglobulinemia (Glovsky and Fudenberg 1970), arthritis
-19-
with cutaneous vasculitis (McDuffie et al. 1973), and polyarter-
itis (Gocke et al. 1970). Changes in the complement catabolic
rate have also been associated with disease processes, such as
Ankylosing Spondylitis (Brinch 1982).
Local formation of immune complexes with consequent comple-
ment cleavage leads to the development of inflammatory disease
within a specific organ or extravascular site. For example,
analysis of synovial fluid, cerebral spinal fluid, or pleural
effusions may reveal immunopathologic processes not necessarily
detectable in peripheral blood. Rheumatoid arthritis (RA) is
though to have an immune complex-mediated inflammation ,centered
primarily in the intra-articular region. The immune, complexes
present in RA consist of Rheumatoid Factor (IgG, IgA, and IgM
immunoglobulins) in combination with IgG antigen or self-assoc-
iated aggr.egates of IgG rheumatoid factors (Winchester et al.
1970). These complexes (especially IgM) activate complement
(Townes and Marcus 1972, Tanimoto et al. 1975) through the class-
ical pathway and then are phagocytized by the infiltrating poly-
morphonuclear leukocytes with consequent tissue damage. Evidence
to support this concept of RA etiology is strong. Immunoglobu-
fins, Clq, C4, and C3 have been found within the intra-articular
phagocytic cells (Hollander et al. 1965) and deposited in the
synovial lining tissue when examined with immunofluorescence
(Britton and Schur, 1971). In addition, the RA synovium is
heavily infiltrated with mononuclear cells, including macrophages
(Ishikawa and Z iff 1976) and many plasma cells with a high rate
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of synthesis of immunoglobulins, including rheumatoid factor.
Rheumatoid synovial tissue has been shown to synthesize many
complement components: C2, C3, C4, and C5 (Ruddy and Colten 1974,
Whaley 1980) and C2, B, D, P, I and H (DeCeulaer 1980). There-
fore, within the synovium all the participants necessary for
complement-mediated immune complex-induced inflammation are pre-
sent.
Considerable additional evidence adds support to the impli-
cation of complement-fixing immune complexes in the pathogenesis
of rheumatoid arthritis. Synovial fluid in RA patients has been
shown by several investigators to have depressed whole complement
levels (Pekin and Zvaifler 1964, Hunder et al. 1977). Individual
complement components also are reduced in the synovial fluid of
these patients; depressed C4 levels are most consistent (Hunder
and McDuffie 1973). Serum from RA patients may also have low
levels of C4, but most have normal or even elevated levels in
serum when rheumatoid vasculitis is not present (Franco and Schur
1971, Ruddy and Austen 1970, Versey et al. 1973). In addition,
the few with decreased complement serum levels have more severe
disease and high rheumatoid factor titers (Ruddy and Austen 1970,
Vaughan et al. 1968). Perrin et al. (1977) observed significant-
ly increased levels of breakdown products of C3, C4, and B in the
joint fluid from RA patients when compared with osteoarthritis
patients. The parallel increase of C3d (Nydegger et al. 1977),
C4d and Ba levels in the RA patients suggest true activation of
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the complement system rather than a non-specific enzymatic break-
down in the synovial fluid. C3 conversion was found in all
synovial fluids of sero-positive RA patients tested by Hunder et
al. (1977), with an accelerated functional catabolic and synthe-
sis rate of C3 measured using radio-labelled C3 (Weinstein et al.
1972, Ruddy et al. 1975). C3 levels in sero-positive RA were
shown to be decreased when measured by radial immunodiffusion
(Ruddy et al. 1969), crossed immunoelectrophoresis (Hedberg 1964)
or hemolytic titration (Ruddy and Austen 1970) methods. Low
levels of both C2 and C4 suggest that the lowered synovial fluid
complement levels are due to classical pathway activation (Ruddy
and Austen 1970, Gabay et al. 1975).
Winchester et al. (1969) established a correlation between
the amount of immunoglobulin-containing complexes and the diminu-
tion of total hemolytic complement activity in synovial fluid
from patients with sero-positive R This was also confirmed by
Townes and Marcus (1972). In addition, it has been demonstrated
that complement proceeds to cytolytic completion in the RA joint
space. Ruddy et al. (1971) found decreased C9 levels in joint
fluid and Dourmaskin and Patterson (1976) observed membrane le-
sions in synovial cells characteristic of the membrane attack
complex using electron microscopy.
Complement activation by the classical pathway thus appears
to be a factor in RA with intra-articular cleavage of C3, its
deposition in tissues with PMN phagocytosis and appearance of
cleavage fragments. However, the alternative pathway components,
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B and P, have diminished levels in RA joint fluid and their
cleavage products also appear in these fluids (Zvaifler 1974,
Ruddy et al. 1975b, Lambert et al. 1975). Increased catabolism
of B has been demonstrated in the serum of patients with RA
(Krick et al. 1978). Kaplan et al. (1980), using radio-iodide
labelled C4 and B, concluded that the C4 fractional catabolic
rate was predominant over the B fractional catabolic rate. He
found that the catabolism correlated significantly with rheuma-
toid factor, supporting the concept of RA as a systemic, extra-
vascular immune complex disease with rheumatoid factor immune
complexes playing a significant pathogenic role through the acti-
ration of the classical complement pathway, with the alternative
activating pathway acting in an amplifying role. However, Hunder
et al. (1979) showed that direct activation of the alternative
pathway in RA is also possible. Using C4-deficient serum, he
observed complement cleavage induced by unidentified substances
in the sera and synovial fluid of RA patients. The amount of
complement cleavage was approximately the same whether the clas-
sical pathway was operational or not. Other investigators have
demonstrated that Type I and Type II collagen are able to induce
C3 and B conversion in both normal and C4-deficient serum, sug-
gesting a mechanism for the direct alternative pathway activation
in RA synovial fluid (Takahashi et al. 1975).
The alternative pathway has been shown to be active in a
number of other pathologic conditions. Complement activation as
evidenced by hypercatabolism of serum C3 has suggested a role for
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complement in Ulcerative Colitis and Crohn’s Disease (Hodgson et
al. 1977), involving the activation of complement within the
inflamed gastrointestinal mucosa and sequestration of C3 in the
extravascular space. Lake et al. (1979) observed abnormalities
of the alternative pathway (decreased serum P) in the serum of
patients at the time of diagnosis of inflammatory bowel disease,
especially regional enteritis and Crohn’s disease. The classical
pathway appeared intact in this study.
Other diseases are characterized by aberrations in the al-
ternative pathway. Membranoproliferative glomerulonephritis and
partial lipodystrophy (Peters et al. 1972) have been associated
with a prolonged reduction in total serum hemolytic complement
(low serum C3 with normal CI, C4, and C2 (West et al. 1965)).
Investigators have described C3 Nephritic Factor present in the
serum of some of these patients (Spitzer et al. 1969). C3 Neph-
ritic Factor is an IgG autoantibody capable of activating the
alternative pathway of complement by combining with and stabili-
zing C3b, B convertase (Fearon et al. 1975), therefore causing a
rapid consumption of C3. Peters et al. (1972) examined 15 pa"
tients with this disease and found reduced levels of C3 and C7 in
the serum, with C3 breakdown products and C3 Nephritic Factor
also present. In addition, C3 and immune complex deposits were
present in the kidneys.
Another disease, Paroxysmal Noctural Hemoglobinuria, has
also been linked to the activation of the alternative pathway.
It is an acquired disorder of erythrocyte membranes which
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heightens their susceptibility to complement-mediated lysis. The
erythrocytes therefore have a shortened life span (Hinz et al.
1956).
In gram negative bacteremic individuals, decreased serum C3
levels have been associated with shock (McCabe 1973). P, C3, C5,
C6, and C9 levels are lower in bacteremic individuals with shock
than in those not in shock. Palestine and Klemperer (1976)
observed circulating B cleavage products in normotensive bacter-
emic patients, despite the presence of normal or even elevated B
levels, suggesting involvement of the alternative pathway.
Complement an__d Periodontal Disease
Chronic inflammatory periodontal disease, the major cause of
tooth loss in adults, is characterized by infiltration of the
gingival tissues by inflammatory cells and loss of connective
tissue substance. Page and Schroeder (1976) have described the
various stages of the progression of periodontal disease. The
initial lesion, which occurs after a few days accumulation of
microbial plaque, is characterized by acute exudative vasculitis,
edema, loss of per ivascular collagen, and the presence of PMNs
intercellularly migrating through the gingiva into the sulcus.
PMNs are present in the progressing lesions, also. The early
lesion, which develops within four to ten days of plaque accum-
ulation, consists of a dense infiltrate of small lymphocytes and
other mononuclear cells, accompanied by degenerative change in
fibroblasts and continued loss of connective tissue substance.
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The established lesion, present in two to three weeks, reveals a
predominance of plasma cells, and may remain stable for several
years, or progress to the advanced lesion. The advanced lesion
is characterized by a loss of alveolar bone and periodontal
ligament, many plasma cells, fibrosis, bone resorption and
destruction of the normal periodontal architecture.
Since the histopathologic features of periodontal disease
are similar to other chronic inflammatory disease processes which
involve the complement system, the potential role of the comple-
ment system in the initiation and progression of acute and chro-
nic periodontal inflammation has been the subject of considerable
study. Analyses of the exudate of periodontal lesions, gingival
fluid, have provided an avenue for examination of the complement
system. Several investigators have confirmed that gingival fluid
is an altered inflammatory exudate. This has been accomplished
by examining the proteins (Brill and Bronnestrom 1960, Mann and
Stoffer 1964, Weinstein and Mandel 1964, Schenkein and Genco
1977a), carbohydrates (Hara and L6e 196 9), ions (Krasse and
Egelberg 1962), and enzymes (Gustafson and Nilssen 1961, Frank
and Cimasoni 1972) present in gingival fluid and comparing them
with serum content. However, studies of gingival fluid are
hindered by the small amounts which can be collected and by the
vast assortment of microbial and host-derived substances which
are present.
Complement components have been identified in gingival
fluid. Shillitoe and Lehner (1972) observed concentrations of C3
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in gingival fluid which were somewhat less than those found in
serum. Courts et al. (1977) noted the existence of a functional
complement system in the gingival fluid of patients with perio-
dontitis. The authors reported that the addition of dental
plaque to gingival fluid led to Cl fixation and they determined
both ci hemolytic activity and whole complement hemolytic activi-
Complement utilization appears to be associated with perio-
dontal disease. Reduced levels of native C3 and C4 (Attstrom et
al. 1975, Schenkein and Genco 1977a) relative to other serum
proteins have been found in the gingival fluid obtained from
severe periodontal lesions. Schenkein and Genco (1977a) observed
that native C3 in gingival fluid from diseased sites was approxi-
mately25% of the serum level while other serum components of
similar molecular weight existed at 80% of serum levels. Activa-
tion of C3 in gingival fluid obtained from periodontal lesions
has been suggested by the presence of its cleavage products, C3c
(Attstrom et al. 1975, Schenkein et al. 1976, Schenkein and Genco
1977b) and C3d (Schenkein and Genco 1977b). Patters et al.
(1979) reported a larger percent of C3 cleavage in gingival fluid
from inflamed sites when compared with healthy sites. C4c, a
conversion product of C4 (Shiraishi and Stroud 1975) has been
observed in the gingival fluids of patients with juvenile perio-
dontitis (Schenkein et al. 1976) and in some patients with severe
rapidly progressive periodontitis (Schenkein and Genco 1977b).
The cleavage product of B, Bb, has been detected in the gingival
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fluid from severely diseased sites (Attstrom et al. 1975,
Schenkein et al. 1976, Schenkein and Genco 1977b). In all
patients examined in these studies, no complement cleavage pro-
ducts were observed in serum.
Additional indirect evidence exists to support the concept
of complement cleavage in periodontal disease. Extracts of gin-
gival tissues from patients with periodontitis were observed to
be chemotactic for monocytes (Okada and Silverman 1979). This
was not true for tissue from healthy subjects. Antibodies to C5
substantially inhibited this chemotactic activity. In addition,
these gingival extracts induced chemotactic activity from fresh
serum. Complement-related compounds may, therefore, be important
in the chemotaxis of mononuclear cells in periodontal disease and
in the change of predominant cell type that occurs.
The above studies do not address the mechanism or the loca-
tion of the complement conversion in the periodontal diseases.,
but many of the initiating factors of both the classical and the
alternative pathways are present in the periodontium. Bacteria
and their products, immunoglobulins, and complement components
are all located in the area of the periodontal pocket, supporting
the concept of a potential role for complement in periodontal
disease.
Although immune complexes have not been identified in
tissues taken from either dogs or humans with chronic perio-
dontitis (Clagett and Page 1978), other evidence suggests a role
for the classical pathway of complement activation in periodontal
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disease following the interaction of antigens and antibodies.
Immunoglobulins were first described in gingival fluid by
Brandtzaeg (1965). Several laboratories since have identified
predominantly IgG, but also IgA without a secretory piece
(Holmberg and Killander 1971), and IgM in gingival fluid
(Shillitoe and Lehner 1972, $chenkein and Genco 1977a). Anti-
bodies also have been demonstrated in the serum of individuals
with periodontal disease that are reactive with many species of
periodontopathic bacteria, including Actinomyces. Actinobacillus,
Bacteroides,_ Fusobacteria and Leptotrichia (Mergenhagen et al.
1965, Genco et al. 1974, Evans et al. 1966, Mansheim etal.
1980). In juvenile periodontitis patients, high serum and gingi-
val fluid antibody titers to Actinobacillus actinomvcetemcomitans
have been observed. Additionally, local synthesis within the
gingival tissues of antibodies and complement have been reported
(Schlossberg 1971, Payne 1975). Gingival plasma cells have been
shown to synthesize immunoglobulins specific for oral bacterial
antigens. Berglund (1971) demonstrated antibody activity in
extracts of inflamed gingival tissue. Results have been conflic-
ting in determining the type of immunoglobulins produced within
the periodontium; Brandtzaeg (1965) noted primarily IgG pro-
duction, Platt et al. (1970) IgM, and Mackler et al. (1978):
IgGI, IgG3, IgG4. Lally and coworkers (1980), using 14C-labelled
amino acids with immunoelectrophoresis and autoradiography, de-
tected IgG and IgA synthesis locally in chronically inflamed
gingival tissues. They observed no immunoglobulin synthesis in
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healthy gingival tissue. Using a similar method, Lally et ai.
(1982) demonstrated local biosynthesis of C3 and C5 in the major-
ity of individuals with chronically inflamed gingiva, but not in
healthy tissue. Immunofluorescent studies have been reported
which describe IgG, IgM, and C3 within the gingival tissues of
gingivitis (Toto et al. 1978a) and periodontitis (Toto et al.
197 8b).
Investigators have used immunofluorescent techniques to
determine the presence of immunoglobulins and complement bound to
subgingival bacteria. Only a fraction of the total bacteria in
each smear were positive for the immunoglobulins or complement
(Platt et al. 1970, Genco et al. 1974). Nisengard and Jarrett
(1976), however, reported that all bacterial samples obtained
from periodontitis and most from gingivitis revealed
_
vivo
coating of some bacteria with IgG, IgA, IgM, IgE, and/or comple-
ment. Recently, bacteria coated with Clq and C4 have been demon-
strated in dental plaque from chronic periodontitis pockets,
visualized by light and electron microscopy with specific anti-
bodies to human Clq and C4 and reacted with peroxidase-antiper-
oxidase (Chisikovsky et al. 1982). Many constituents of dental
plaque have been shown to consume complement by the alternative
activating pathway or the classical pathway, or both. Okuda and
Takazoe (1980) observed complement cleavage in all sera following
exposure to dental plaque. viscosus,
_
m_elaninogenicus,
_
oralis,_po!ysaccharide from
_
mutans, S. sanguis, F_ nucleatum
cell wall and other oral bacteria cause complement activation
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(Ni!sson et al. 1975, Allison et al. 1976, Shivers et al. 1974,
Hawley and Falker 1977). The incubation of dental plaque and
serum results in the production of a factor which causes hist-
amine release from basophils. This factor is inhibited by anti-
body to C5 and it is thought to be C5a (Olsson-Wennstrom et al.
1978). This abundance of oral bacteria, both Gram-positive and
Gram-negative, capable of activating complement through the
alternative pathway, and the presence of specific antibodies
strongly suggests that many of the inflammatory events associated
with periodontal inflammation are complement-related.
Studies in decomplemented animals provide further support, to
the importance of complement in periodontal disease. Dogs,
immunized with plaque extract and decomplemented with carraghee-
nan (prevents complement activation by blocking the reaction
between Cl and the immune complexes (Borsos et al. 1965, Ward and
Cochrane 1965) showed markedly diminished PMN migration and vas-
cular exudation when challenged with plaque extract (Kahnberg et
al. 1977). However, when Cobra Venom Factor (a C3b analog and
alternative pathway activator) decomplemented dogs which had not
been previously immunized were challenged with dental plaque,
only a minor change was observed in the number of leukocytes in
the challenged junctional epithelium (Kahnberg et al. 1976). The
vascular response to the applied plaque extract was decreased in
these decomplemented dogs, however. Wennstrom and coworkers
(1980) applied extracts from pure cultures of _Actinomyces vis-
cosus and Cap_nocytophaga ochracea to the gingival margin of Cobra
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Venom Factor decomplemented dogs and observed a markedly dimin-
ished leukocyte accumulation in the junctional epithelium, sug-
gesting that complement plays an in vivo role in leukocyte chemo-
taxis and gingival inflammation.
Other consequences of complement activation correspond with
events in periodontal disease. Complement cleavage generates
mediators of vascular and cellular inflammatory phenomena through
chemotaxis, anaphylatoxin production and host and bacterial cyto-
toxicity. In addition, the opsonizing effect of C3b, important
in host defense in the gingival sulcus, contributes to tissue
damage by release of histolytic enzymes by phagocytizing cells.
C3b also induces the release of lymphokines from lymphocytes, and
has been implicated in stimulating the release of hydrolytic
enzymes from macrophages (including collagenase and elastase),
resulting ultimately in connective tissue destruction, a hallmark
of periodontal disease. Complement has also been linked to bone
resorption, an important phenomenon in periodontitis. Fetal rat
bone resorption was observed when bone cultures were incubated in
fresh rabbit serum. The resorption did not occur when the bones
were cultured in heated rabbit serum or C6-deficient serum but
recurred when purified C6 was added (Raisz et al. 1974). The
mechanism of complement cleavage in gingival fluid in periodontal
disease is unknown, but it is clear that C3 is degraded to its
final products. This can be achieved by i) activation of the
classical pathway, 2) initiation of the alternative activating
pathway, or 3) non-complement proteolytic cleavage of complement
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components. The presence of constant antigenic challenge in the
periodontal pocket, plaque-specific serum antibodies and the
observation that plasma cells are found in tissues adjacent to
the pocket, suggest the potential for antigen-antibody reactions
with consequent classical pathway complement activation. Experi-
mentally, Arthus reactions induced in the gingiva of immunized
monkeys resulted in an inflammatory infiltrate and osteoclastic
resorption similar to that found in periodontitis (Nisengard et
al. 1977). IgG and C4 deposits were observed in perivascular
areas in these animals. It is therefore possible that specific
antibodies which reach the periodontal tissues via serum and
locally synthesized immunoglobulins with specificity for bacter-
ial antigens may interact with bacteria and their products to
initiate classical pathway activation.
The diseased gingival tissues contain endotoxin and other
bacterial products capable of fluid-phase alternative pathway
activation. In addition, cleavage of complement components by
non-complement proteolytic enzymes may also occur.
It is clear that the activation of complement plays an
important role in the mediation of inflammation in many chronic
inflammatory diseases. Conversion products of C3, C4, and B have
been reported to be present in gingival fluid from severe perio-
dontitis lesions. Because of the limited amounts of gingival
fluid available from lesions of minimal inflammation, no longitu-
dinal studies of complement activation in periodontal disease
have been reported. Using an assay developed by the Master’s
candidate, sufficient sensitivity is now available to assess
longitudinal changes in complement conversion in periodontal
disease. Therefore, the purpose of this study was to determine
the extent of conversion of complement components of both the
classical and alternative pathways in human gingival fluidob-
tained from lesions of chronic periodontitis, prior and subse-
quent to initial periodontal treatment. The differences in the
measured extent of conversion of the complement components C3,
C4, and B from the same site were statistically compared before
and after therapy. The information gained may provide a better
understanding of the role of complement activation in the initia-
tion and progression of periodontal disease.
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SPECIFIC OBo-EC
The specific objectives of this study were to:
i) develop a sensitive method to simultaneously assay C3, C4,
and B conversion from a single gingival fluid sample
2) nieasure the extent of conversion of C3 in gingival fluid
from patients with chronic periodontitis
3) measure the extent of conversion of C4 in gingival fluid
from patients with chronic periodontitis
4) measure the extent of conversion of B in gingival fluid from
patients with chronic periodontitis
5) determine the differences in the measured extent of conver-
sion of C3, C4, and B in gingival fluid from the same perio-
dontal sites after initial periodontal therapy.
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MATERIALS and METHODS
Se!e.ction o_f_subjects Participants were selected from pa-
tients presenting for treatment at the out-patient clinics of the
University of Connecticut School of Dental Medicine. The nature
and risks of the study were explained to all participants and
informed consent was obtained. Subjects received a complete oral
examination including Gingival Index (L6e and Silness 1963),
Plaque Index (Silness and Le 1964), measurement of pocket depth
and loss of periodontal attachment in millimeters, presence of
suppuration and bleeding on probing (recorded as 1 if present, 0
if absent). These indices were recorded at a visit prior to the
initial sampling, and confirmed immediately subsequent to sam-
pl ing.
Subjects chosen for study had clinical and radiographic
evidence of 20 to 50% bone loss on many teeth. The severity of
periodontal disease in this group was consistent with that which
would be expected due to age and local factors. Subjects ranged
in age from 40 to 60 years, and had a mean Plaque Index greater
than I, with pocket depths of 4-9 mm, and loss of attachment
ranging from 1-9 mm.
Gingival fluid from nine individuals with chronic periodon-
titis was obtained at selected times before and after treatment
from representative sites. In some patients, samples were taken
twice prior to treatment (baseline). The subjects were then
instructed in oral hygiene (brushing and flossing) and received
thorough mechanical debridement (root planing and scaling). Sites
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were sampled again at 2-4 weeks after therapy. All clinical
indices were repeated after each sampling. Some sites were
sampled twice (2 and 4 weeks) after therapy. Blood samples were
also taken at the initial visit and serum separated.
Collection o_ gingival fluid: The sites selected for study
were interproximal areas which best reflected the disease status
of the patient. Standardized filter paper strips (PER-601, Harco
Electronics, Winnipeg, Manitoba), wetted with 0.01M Na2EDTA and
completely dried before use to prevent C4 conversion upon elec-
trophoresis (Sjoholm and Laurell 1973), were inserted a pre-
marked length (3 mm) into the pocket and allowed to remain undis-
turbed for 3 min. Prior to fluid collection, the tooth was
gently washed with water, dried with air and isolated with cotton
rolls. Samples contaminated with blood or plaque were discarded.
The samples were then placed in individual plastic containers
coded by a person other than the investigator and subjected to
crossed-immunoelectrophoresis within 1 hr.
Antisera: Solid-phase absorbed antisera specific for C3
(beta-l-C, beta-l-A), C4, transferrin, and B, respectively, were
obtained from Atlantic Antibodies (Scarborough, Maine) and tested
for specificity by immunoelectrophoresis vs. human serum. Fresh
serum and zymosan-activated serum served as negative and positive
controls, respectively, for C3 conversion to C3c and B conversion
to Bb. EDTA-anticoagulated plasma and immune-complex treated
serum (Sjoholm and Laurell 1973) were used as negative and posi-
tive controls, respectively, for C4 conversion to C4c.
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o_f ComplemenZ Components Gingiv_a! F_: Comple-
ment conversion was assessed by crossed immunoelectrophoresis.
The coded filter paper strips were removed from their containers,
trimmed to 5 mm in length, positioned over a 1.6 mm hole cut in
agarose, and folded into the hole with a sharp instrument
(Patters et al. 1979). Fluid components migrated out of the
strip into the agarose when electrophoresis was begun.
First dimension electrophoresis was carried out in 1.0%
agarose (SeaKem) in barbital buffer (pH 8.6, ionic strength=0.02)
containing 0.01M Na2EDT;U An 8 volts/cm current was applied to
the 1.5 mm thick gel containing the filter paper strips for 90
min at 15C.
Second dimension electrophoresis was carried out using a
technique developed by the Master’s candidate, in which the
conversion of C3, C4, and B could be simultaneously assayed from
a single gingival fluid sample. The first dimension gel was cut
with a razor blade into a 1 cm slab containing the filter strip
and its migrated components and transferred to a 50x50xl mm glass
plate. Agarose (3.1 ml) containing a predetermined optimal con-
centration of specific antisera to B and to C3 was poured onto
the remaining 4 cm of the plate. After this gel had solidified,
2.0 cm of this agarose was rtemoved, leaving the 1 cm wide first
dimension gel and 2.0 cm of anti-B and anti-C3. Finally, 1.5 ml
of agarose containing specific antisera to C4 and to human trans-
ferrin (reference protein) was poured onto the remaining part of
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the plate. In this manner, a 50x50xl mm gel had been formed con-
taining the first dimension gel, a 2.0 cm wide slab of agarose
with anti-B and anti-C3, and a 2.0 cm wide gel containing anti-C4
and anti-transferrin.
The solidified gel was placed on the electrophoresis appar-
atus at 90 to the direction of the first dimension with the
first dimension gel toward the cathode. The gel was connected
with the buffer by means of filter paper wicks. Current
(2volts/cm) was then applied at 15C for 16 hours. The gels were
rinsed with distilled water, dried at 60C., and stained with
Coommassie Brilliant Blue R-250, and the precipitates measured as
described below.
The areas under the curve formed by each precipitate were
estimated on a 7X magnified projection by measuring the rocket
height and multiplying by the rocket width measured at one-half
the rocket height (Weeke 1973). The percentage of C3 converted
to C3c was then determined by the following formula:
%C3 conversion Area.. of the C3C. rocket
Area of C3c rocket + Area of C3 rocket
x i00
Conversion of C4 to C4c was assessed by appearance of a less
anodally migrating rocket when compared with C4 in EDTA-contain-
ing serum. Transferrin, which produced a single rocket which
migrated reproducibly between the C4 and C4c rockets, served as a
marker to aid in the identification of a single rocket as either
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C4 or C4c (Scharfstein et al. 1978). The percentage of C4 con-
version was calculated as described for C3c/C3. Because of the
heterogeneity of human C4, serum samples were used as controls to
indicate the migration pattern of C4 for that individual.
B produced a single rocket which migrated anodally, while
Bb, under the conditions of pH and buffer strength used, produced
a rocket with minimal gamma mobility. Since the Bb rocket was
always small, quantitative measurements were not possible.
Codes were broken after the gels were analyzed.
Statistical analys_es. Statistical significance of longi-
tudinal changes in clinical indices and complement conversion
following therapy was assessed by both parametric and non-para-
metric methods. Interval data (pocket depth, loss of attachment,
area of precipitates formed by complement components, and percen-
tage conversion) were analyzed using the correlated (paired) t-
test. Using this test, t is determined by dividing the mean of
the differences between pairs by the standard error of the mean
difference. The probability value, p, is found from t at the
degrees of freedom equal to the number of pairs minus one. Non-
interval data (plaque index, gingival index, bleeding on probing,
and suppuration) were analyzed using the Wilcoxon matched-pairs
signed rank test. In this test, the differences between pairs
.are ranked and the smaller of the sums of the positive or nega-
tive ranks is T. Although means and standard deviations are
presented for descriptive purposes, they were not used in the
statistical analyses of non-interval data.
Method: To establish the crossed-immunoelectrophoresis
method introduced in this study, fresh serum was used as the
negative control. Zymosan-activated serum served as the positive
control for C3 and B conversion and immune-complex activated
serum was utilized as the positive control for C4 conversion.
The concentrations of antisera in the gels were adjusted to
achieve C3, C4, and transferrin rockets with an area of approxi-
mately i000 units on the 7X projection when 0.5 ul of serum was
used. The optimal concentrations for these antisera were 2.0
ul/ml agarose for anti-C4, 1.4 ul/ml agarose for anti-C3, and i0
ul/ml agarose for anti-transferrin. Due to the low concentration
of B in serum, rockets of this magnitude were never possible.
Therefore, the Anti-B antiserum was adjusted to a concentration
of 4.0 ul/ml agarose, which produced a rocket of about 250 units
on the 7X projection from 0.5 ul of serum. Bb appeared only as a
flat unmeasurable precipitate, and thus was recorded only as
present or not present. Throughout the course of this study, a
single lot of each antiserum was used.
Precipitates formed by multi-dimension crossed-immunoelec-
trophoresis were compared with those from standard crossed-
immunoelectrophoresis using a single antiserum. The precipitates
of all proteins examined- C3, C3c, C4, C4c, B, Bb and transfer-
rin were of similar area and mobility when compared to the multi-
layer gels. Therefore, the multi-dimension technique did not
cause significant distortion of the precipitates.
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Reproducibilty o_ Method-_. To establish the reproducibility
of the method, 26 sites were examined twice prior to treatment.
Additionally, 16 sites were sampled two times post-treatment.
Analysis of the two pretreatment sample plaque index values by
Wilcoxon (for non-interval data) revealed a significant variation
between Time 1 and Time 2 (p<=0.005, Table i). During this time,
the plaque index declined from a mean of 1.88 (Time I) to 1.35
(Time 2). Comparis.on of the two post-treatment plaque index
values showed no significant difference between Time 3
(mean=0.63) and Time 4 (mean=0.75).
Wilcoxon analysis of the two pretreatment gingival index
values (Table 2) disclosed no significant variation between Time
1 (mean GI=1.54) and Time 2 (mean GI=1.35). Also, no significant
difference existed between the post-treatment values, (Time 3
mean GI=I.12) and Time 4 (mean GI=1.25).
The two pretreatment values for bleeding on probing (Time 1
mean bleeding on probing=0.81, Time 2=0.73) were not significant-
ly different (Table 3). Comparison of the two post-treatment
mean bleeding on probing values showed no significant variation
(Time 3=0.50 Time 4=0.63). Analysis of the two pretreatment and
the two post-treatment suppuration values by Wilcoxon revealed no
significant changes in either comparison (Table 4).
The correlated t-test was used for analysis of the interval
data. Table 5 contains the values for the reproducibility of
pocket depth measurements. No significant change in pocket depth
occurred between the two pretreatment values (Time 1 mean pocket
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depth=6.38 mm and Time 2 mean pocket depth=6.46 mm). However, a
slight but significant difference was apparent between the two
post-treatment readings (p=0.015). The Time 3 mean pocket depth
was 5.81 mm and the Time 4 mean pocket depth was 5.31 mm.
Loss of attachment reproducibility analysis followed a simi-
far pattern (Table 6). Using the correlated t-test, no signifi-
cant variation was found between the two pretreatment values
(Time I mean loss of attachment=5.38 mm and Time 2 mean loss of
attachment=5.19 mm). There was a small but significant differ-
ence between the two post-treatment measurements (p<0.0034).
The Time 3 mean loss of attachment was 6.00 mm and the Time 4
mean loss of attachment equalled 5.38 mm.
Table 7 contains the reproducibility analysis of the per-
centage C3 conversion by correlated t-test. The mean percentage
of C3 conversion was 78.2% and 62.2% for Time 1 and Time 2,
respectively. No significant differences were apparent between
the two pretreatment or between the two sets of post-treatment
percentage C3 conversion values (Time 3=51.4% and Time 4=39.4%).
Therefore, for all pretreatment parameters measured on two
occasions only the plaque index differed significantly. In com-
paring the two sets of post-treatment values, a slight but signi-
ficant decrease in both pocket depth and loss of attachment
occurred between Time 3 and Time 4. All other variables examined
did not significantly differ.
Clinical Lo_ngitudinal Results- For analysis of the changes
in the clinical variables over the course of treatment, 37
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chronic periodontitis sites were examined. Time 1 values were
compared with Time 4 values. Wilcoxon analysis was employed for
non-interval data and correlated t-test for interval data.
Comparison of plaque index values (Table 8) revealed a
significant decrease (p<=0.005) following periodontal treatment.
The pretreatment plaque index mean was 1.76 and the post-treat-
ment plaque index mean equalled 0.95. The Gingival Index fol-
lowed a parallel pattern (Table 9), and declined significantly
(p<=0.005) between pretreatment and post-treatment measurements.
The mean pretreatment GI was 1.54 and the mean post-treatment GI
was I.ii. Bleeding on probing (Table I0) also showed a signifi-
cant decrease after periodontal treatment (p<=0.005), decreasing
from a pretreatment mean of 0.86 to a post-treatment mean of
0.41. Suppuration values (Table Ii) declined significantly
(p<=0.025) over the course of treatment. The mean pretreatment
suppuration value was 0.22, but the post-treatment mean was 0.05.
From the correlated t-test analysis of pocket depth measure-
ments (Table 12), it was apparent that a highly significant
decrease (p<=0.00005) occurred between the pretreatment measure-
ments (mean pocket depth=6.32 mm) and the post-treatment values
(mean pocket depth=5.05 mm). A reduction in loss of attachment
(Table 13) was also highly statistically significant
(p<=0.00005), changing from a pretreatment mean of 5.65 mm to a
post-treatment mean of 4.84 mm.
ople_men___t and Transferrin LoDgitudi.na! Res..ults: For
analyses of the changes in complement cleavage during periodontal
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Therefore, several significant changes in complement corn-
ponents occurred following periodontal treatment. The area of
the C3 precipitate increased; the area of the C3c precipitate
decreased, and the percentage of C3 conversion declined sharply.
C4, C4c, B, Bb and transferrin did not show any statistically
significant change.
Figure 1 is a photograph of a gel from a gingival fluid
sample taken prior to periodontal treatment. Precipitates rep-
resenting transferrin (T), C4, C3, C3c, B, and Bb are visible.
Approximately 60% of the available C3 has been converted to C3c.
Figure 2 is a photograph of a gel obtained after crossed-immuno-
electrophoresis of gingival fluid taken from the same site as in
Figure I, but sampled following periodontal therapy. Again pre-
cipitates representing transferrin (T), C4, C3, C3c, B and Bb can
be observed. The C3c rocket is diminished in area relative to
the C3 rocket in this post-treatment sample and represents 27% C3
conversion.
DISCUSSION
The Method. The sampling and crossed immunoelectrophoresis
technique introduced in this paper was highly sensitive and
allowed the assessment of the complement components from a single
gingival fluid sample obtained from a specific site. No pooling
of samples was necessary as the proteins could be measured in
gingival fluid samples as small as 0.2ul. Since no elution of
the samples was required, the dilution of C3 beyond detectable
levels as occurred in the report of Attstrom et al. (1975) was
also avoided. The sensitivity of the new procedure and the
sampling method, therefore, allowed the analysis of complement
components in areas of minimal periodontal inflammation, making
possible a longitudinal study of complement activation in chronic
periodontitis over the course of treatment. No previous longitu-
dinal studies of complement activation in gingival fluid have
been reported. Additionally, it was possible to ascertain not
only whether the complement terminal pathway was activated by the
presence of C3 conversion products, but also which initiation
pathway might be utilized. If C4 cleavage products are present,
then the classical pathway is likely activated. If B cleavage
products can be observed, alternative pathway initiation is sug-
gested.
Reproducibility of th9 method. The major objective of this
study was to determine longitudinal changes in complement cleav-
age in gingival fluid that occurred with treatment of the perio-
dontal lesions. Prior to making these observations, it was
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necessary to determine the stability of the clinical and comple-
ment measures. Therefore, a subset of periodontal lesions was
assessed clinically and for complement cleavage on two occasions
prior to and two occasions after therapy. A comprehensive clini-
cal examination was performed at both pretreatment and both post-
treatment visits and included the plaque index (Silness and Le
1964), gingival index (Le and Silness 1963), bleeding on pro-
bing, suppuration, pocket depth and loss of attachment in milli-
meters, all recorded after the gingival fluid samples were taken.
In comparing Time 1 with Time 2 samples (Table I), only the
plaque index decreased significantly (p<=.005). This improvement
in the plaque index can be attributed to the fact that the pa-
tient had started a series of periodontal treatment visits and
had received some hygiene instruction. All other clinical para-
meters and complement component measurements were not statistic-
ally different between Time I and Time 2 (Tables 1-7). In addi-
tion, reproducibility of complement component measures between
the two pretreatment samples was excellent. Therefore, Time 1
values were selected for further statistical comparisons.
Identical periodontal sites were also examined and sampled
at two and four weeks post-treatment. Comparison of the two
posttreatment samples revealed a small decrease in pocket depth
(0.5mm) and loss of attachment (0.6mm) with the longer healing
time (Table 5 and 6). This decrease in loss of attachment may be
caused by a decrease in inflammation of the periodontal tissues
with a consequent tighter adaptation of the tissue to the tooth
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and a greater resistance to periodontal probing. All other
clinical parameters and complement measurements did not vary
significantly between the two post-treatment samples. Results
from these experiments indicated that both clinical and comple-
ment parameters appeared reproducible before and after therapy.
Therefore, changes in these measurements after therapy likely
resulted from treatment rather than random fluctuations. For
analysis of the changes occurring longitudinally with treatment,
the first pretreatment sample (Time i) was compared with the last
post-treatment sample (Time 4).
Complement 9.1eavage in per iodontitis. It is clear from the
results of this study that C3 is cleaved to C3c in the gingival
fluid of chronic, untreated periodontal lesions. This observa-
tion is supported by the cross-sectional findings of Attstrom et
al. (1975), Schenkein and Genco (1977a), and Patters et al.
(1979). The cleavage of C3 may be caused by three primary mech-
anisms: classical pathway, alternative activating pathway, or
proteolysis due to enzymes present in the periodontal pocket.
With the continual presence of antigenic challenge and the
observation of IgG antibodies reactive with oral bacterial anti-
gens in the gingival fluid, it is feasible that a local antigen-
antibody interaction is possible with consequent classical corn-
plement pathway activation. However, few immune complexes have
been observed in the periodontal tissues of chronic periodontitis
(Clagett and Page 1978, Platt et al. 1970, Genco et al. 1974).
In all 37 chronic periodontitis sites examined, C4 cleavage
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products were not observed in the gingival fluid. It therefore,
seems unlikely that .complement activation occurred primarily by
this pathway.
There is evidence that soluble bacterial products capable of
fluid-phase alternative pathway activation (such as endotoxins)
can enter the periodontal tissue through the damaged crevicular
epithelium (Schwartz et al. 1972).. Many agents are capable of
activating the alternative activating pathway of complement, and
several of these are present both in the periodontal pocket and
the surrounding tissue. T-independent antigens and B-cell mito-
gens can activate this pathway. In addition, several bacteria
have been shown to initiate this alternative cascade, including
gram-negative organisms, Actinomyces yscosus and a polysacchar-
ide from StreD.tococcus mutans. Microorganisms are certainly
present in the periodontal pocket and have been observed in the
tissue of severe periodontitis and juvenile periodontitis (Sagli
1982, Frank 1980). Gram negative organisms, including Fusobac,
terium nu_cleatum and Bactero.ides gingivalis found in chronic
periodontitis have been shown to be capable of initiating the
alternative activating pathway (Nilsson et al. 1975, Allison et
al. 1976, Shivers et al. 1974, Hawley and Falker 1977). This
evidence, coupled with the fact that B and its cleavage product
Bb were consistently present in untreated periodontitis, while C4
cleavage products were not, suggests that in the periodontal
pocket, nonspecific direct activation of C3 may occur via the
alternative activating pathway.
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Pro.teoly_tic _Enzymes. C3 and C5 have been split //! by
complement-unrelated enzymes, such as purified neutral proteases
from PMNs (Johnson et al. 1976,. Bronzna et al. 1977, Taylor et
al. 1977). In he above studies, it was observed that elastase,
collagenase and cathepsin G were capable of splitting C3 and C5
into smaller fragments electrophoretically similar to C3a and
C5a. These and similar enzymes may be present in the periodontal
pocket and the possibility does exist that complement cleavage in
periodontal disease occurs by this means. No attempt was made in
the current study to evaluate the contributions of complement-
unrelated enzymes in complement cleavage in the gingival fluid.
Longitudinal changes .f.ollowng peri_odontal therapy. Over
the treatment period, plaque index, gingival index, bleeding on
probing, suppuration, pocket depth, and loss of attachment all
decreased significantly (Tables 8-13). These substantial changes
in the clinical parameters demonstrated the effectivenessof the
initial periodontal therapy. Measurements of transferrin showed
no variation between the pretreatment and post-treatment samples
(Table 19). Transfer r in, a protein unrelated to changes in
inflammation, served as a marker and, therefore, should not have
changed with periodontal treatment. Other factors which might
affect the results were minimized as follows: C4 conversion due
to electrophoresis was suppressed by the treatment of the filter
paper strips used for sampling with Na2EDTA (Sjoholm and Laurell
1973). Samples were processed within one hour to minimize
vitro exposure of the gingival fluid to bacterial plaque on the
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filter strip. Patters et al. (1979) demonstrated that plaque
present on the sampling str.ip did not activate the complement
present in fluid absorbed into EDTA-containing filter paper. In
addition, serum samples from individuals in the study were han-
dled in an identical manner to gingival fluid. No C3, B, or C4
cleavage products were observed in the serum tested and they,
therefore, served as the negative controls. This was especially
critical in the evaluation of C4 which is heterogeneous in humans
and thus has slightly variable mobilities. The transferrin mar-
ker also served to reproducibly distinguish C4 from C4c mobility
(Scharfstein et al. 1978). Immune complex-activated serum served
as the positive control to visualize C4c mobility. Additionally,
clinical measurements and filter strip samples were taken by the
Master’s candidate to eliminate inter-operator inconsistency.
All samples were coded by a person other than the Master’s candi-
date and these codes were not broken until the gels had been
measured. The evidence of clinically successful therapy, the
stability of the reference protein, transferrin, and the above
precautions and controls suggested that any changes in C3, C4 or
B would be the result of therapy rather than random changes.
For all paired samples (pretreatment vs. post-treatment),
however, C3 levels increased (Table 14) and C3c amounts decreased
(Table 15) significantly. Therefore, the percent of C3 conver-
sion also decreased significantly (Table 16, p<0.00005), de-
creasing from 70.0% to 37.5% overall. Less complement cleavage
was therefore present in the gingival fluid after initial therapy
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than in the untreated chronic periodontitis lesions. B (Table
18) and Bb levels did not-change significantly between pretreat-
ment and post-treatment levels, but a trend did exist for
decreased Bb after treatment. This could not be statistically
confirmed due to the difficulty of quantitation of Bb. C4 con-
version products were never observed in the pretreatment samples,
and it remained uncleaved throughout treatment. Native C4 levels
did not statistically change with treatment (Table 17).
This demonstration of a reduction in the C3/C3c ratio fol-
lowing initial periodontal therapy suggests a correlation between
conversion of C3 in gingival fluid and the state of periodontal
health. The observation of complement cleavage products in gin-
gival fluid from diseased sites and an understanding of their
biological implications makes complement-mediated tissue injury a
distinct possibility in periodontal disease. This is underscored
by the fact that the conversion products decrease with a concom-
mitant decline in clinical signs of disease.
Protective and destructive aspects of complement activation.
The activation of complement may play a protective role in the
periodontal tissues. The opsonization of bacteria and their
products, chemotaxis, bacterial cell cytotoxicity, and modulation
of cell-mediated immunity are all first-line defense mechanisms
involving complement. Since the periodontal tissues are con-
stantly challenged by pathogenic bacteria and their toxic pro-
ducts, greater tissue damage than is observed might be expected
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to occur. Chronic periodontitis, however, is a slowly progres-
sive pathologic process. Complement likely figures prominently
in this protectiwe function both through enhanced phagocytosis
and bacteriolysis.
However, activation of the complement cascade induces many
phenomena associated with inflammation and concommitant tissue
damage. This is accomplished in many ways, primarily through the
release of limited proteolytic cleavage products formed by the
complement cascade. The results of this study indicate that the
percentage of C3 cleaved to C3c correlate with clinical measures
of inflammation suggesting an ongoing pathologic process. The
balance between host protection and tissue damage remains to be
determined.
Complement _other _chronic _inflammatory .diseases. Chronic
periodontitis and rheumatoid arthritis are similar in several
ways. They--both involve the development of inflammatory disease
within a specific extravascular site. The majority of inflamma-
tory cells present locally in both disease entities are mononuc-
lear cells. Despite the fact that the involved tissues in both
cases have been shown to contain cells which synthesize many
complement components, complement components in both gingival
fluid (Schenkein and Genco 1977a) and synovial fluid (Pekin and
Zvaifler 1964, Hunder et al. 1977) are at reduced levels. This
suggests that complement may be utilized in both of these disease
processes. In fact, C3 cleavage products are found in both
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synovial fluid (Perrin et al. 1977) and gingival fluid (Attstrom
et al. 1975, Schenkein and Genco 1977b, Schenkein et al. 1976)
from diseased si.tes.
However, t is suggested from this study that the mechanism
of complement utilization may differ between the two disease
entities. Immune complexes are commonly found in RA patients
(Winchester et al. 1970, Townes and Marcus 1972) and are thought
to initiate the complement cascade and contribute to the pro-
gression of the disease. However, immune complexes have not been
regularly observed in chronic periodontitis. Results of this
study indicate that in chronic periodontitis, complement cleavage
occurs primarily via the alternative activating pathway or by
non-complement enzymes. No C4 cleavage (a classical_ pathway
component) was observed in the gingival fluid of these patients.
In RA synovial fluid, C4 is the most consistently depressed
complement component (Perrin et al. 1973) and complement cleavage
is believed to occur primarily through the classical pathway with
the alternative activating pathway in an amplifying role (Kaplan
et al. 1980). It is apparent, therefore, that chronic periodon-
titis is not principally an immune-complex disease, like RA or
SLE, and that complement cleavage does not seem to occur by the
classical pathway. A multitude of factors which initiate the
alternative activating pathway, including bacteria and their
products, arepresent in the periodontal pocket and may explain
the cleavage of complement.
The following conclusions can be made from the studies
preaent:ed in this. thesis
The technique introduced in thi paper wa suitable for the
assessment of complement components C3, C4, and B and their
conversion products. The method was adequately quantitative
for the complement components studied with the exception of
2) C3 is converted to the cleavage product C3c in the gingival
fluid of chronic periodontitis lesions.
3) C4 cleavage products were never identified in thegingival
fluid of chronic periodontitis lesions.
4) B cleavage product, Bb, was present consistently in the
gingival fluid of chronic periodontitis lesions.
5) The percentage of C3 converted to C3c in gingival fluid from
chronic periodontitis lesions decreased significantly fol-
lowing periodontal therapy. This change paralleled the
decline in clinical measurements of inflammatory disease.
55
The development of the new_ sampling method and crossed
immunoelectrophor.esis..technique introduces the possibility for
numerous additional studies. The longitudinal evaluation of
complement changes during treatment should be continued through-
out the surgical phase of treatment. In addition, complement
cleavage in the gingival fluid of patients in the maintenance
phase of periodontal care could be monitored periodically and the
complement changes examined for correlation with clinical mea-
Surements and disease recurrence. Complement cleavage may occur
prior to changes in measurable clinical parameters and, thus,
complement cleavage measurements _could be the first sign of
recurring inflammation.
Other periodontal diseases such as juvenile periodontitis
and rapidly progressive periodontitis could be thoroughly ex-
amined both cross-sectionally and longitudinally to evaluate the
mechanism of complement initiation-and complement changes with
treatment. In a preliminary retx)rt, evidence for C4 cleavage in
juvenile periodontitis was presented by Schenkein and coworkers
(1976), but further studies are indicated. In addition, the
technique presented here is ideally suited for longitudinal anal-
ysis of complement cleavage in experimentally induced gingivitis
because-the small amounts of gingival fluid available from
healthy sites can be analyzed.
To provide further information as to the mechanism of com-
plement cleavage in periodontal disease, the role of complement-
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unrelated proteolytic enzymes could be explored. Radio-labelled
C3 would be incubated with gingival fluid in the presence of an
inhibitor of the complement system such as EDTA or heat inactiva-
tion, electrophoresis conducted, and the amount of labelled C3
converted could be evaluated by autoradiography to establish the
presence of proteolytic enzymes in gingival fluid.
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N
DEVIATION ERROR VALUE VALUE
TIME 1 26 1.88 0.65 0.13 1 3
TIME 2 26 1.35 0.49 0.i0 1 2
WILOOXON T = 0 N=I0 p <= 0.005
N
DEVIATION ERROR VALUE VALUE
T]3 3 16 0.63 0.81 0.20 0 2
TIME 4 16 0.75 0.86 0.21 0 2
WILO0XON T = 10.5 UNTIED N = 7 p= NSb
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.
b) NS = not significant p > 0.05)
LE1
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GINIVAL
DEVIATION ERROR VAI/]E VALUE
TIME 1 26 1.54 0.51 0.i0 1 2
TIME 2 26 1.35 0.49 0.I0 1 2
W]IEOMON T = 18 UNTIEDN= ii
N Sm Sm
DEVIATION ERROR VALUE VALUE
TIME 3 16 1.12 0.34 0.09 1 2
TIME 4 16 1.25 0.45 0 .ii 1 2
WILCOXON T = 7 UNTIED N = 6
a) Means, standard deviations, and standard errors are shcm for
descriptive purposes only and were not used in the statistical
analyses.
b) NS = not significant (p > 0.05)
LE2
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N
DEVIATION ERROR VALUE VALUE
TIME 1 26 0.81 0.40 0.08 0 1
TIME 2 26 0.73 0.45 0.09 0 1
WILOOXON T = 13.5 UNTIED N = 8
N
DION ERROR V VALUE
TIME 3 16 0.50 0.52 0.13 0 1
TIME 4 16 0 63 0.50 0 13 0 1
WILCOXON T = 7 UNTIED N = 6
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.
b) NS = not significant (p > 0.05)
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(E, I--ITIVE)
N
TIME 1 26
TIME 2 26
DEVIATION ERROR VALUE
0.23 0.43 0.08 0 1
o.4o 0.08 o
WILfDXON T = 2 UNTIED N = 3
N
DEVIATION ERROR VALUE VALUE
TIME 3 16 0 0 0 0 0
TIME 4 16 0.13 0.34 0.09 0 1
WILO3XONT= 0 UNTIED N = 2
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.
b) NS = not significant (p > 0.05)
LE4
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TIME 1
TIME 2
N MEAN MIN MAXIM[ MEAN S%DARD ERRCR
VALUE VALUE DIFF OF DIFFERENCE
26 6.38 4 9
26 6.46 4 9
0.08 0.15
t = 0.53 df=25 p = 0.60 (NSb)
TIME 3
TIME 4
N MEAN MINIMUM MAXI MEAN ST ERRCR
VALUE VALUE DIFFERENCE OF DIFFERENCE
16
16
5.81 4 8
5.31 4 7
0.50 0.18
t = 2.74 df=15 p = 0.015
b) NS = not significant (p > 0.05)
TBLE 5
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TIME I
TIME 2
t = 1.15
N
26
26
MEAN MINIMUM MAE[MHM MEAN STANDARD ERRCR
VALUE VAIb DIFFE OF DIFFERENCE
5.38 1 9
5.19 I 9
0.19 0.17
df=25 p = 0.26 (NSb)
TIME 3
TIME 4
N
16
16
MEAN MINIML MAXIMUM MEAN STANDARD ERRCR
VALUE VALUE DIFFERENCE OF DIFFER%?
6.00 4 9
5.38 3 8
0.62 0.18
t = 3.49 df = 15 p = 0.0034
b) NS = not significant (p > 0.05)
LE6
-83-
O C3 (RION
+
TIME i
TIME 2
N MEAN MINIMUM MAXIMUM MEAN ERROR
VALUE VALUE DIFFERENCE OF DIFFERENCE
26 78.2 20.8 i00.0
26 62.2 0 i00.0
16.0 8.4
t = 1.90 df = 25 p = 0.07 NSb)
TIME 3
TIME 4
VATE VAT/E DIFFERENCE OF DIFFERENCE
16 51.4 0 I00.0
16 39.4 0 87.3
12.0 II.7
t = 1.03 df=15 p = 0.32 NSb)
b) NS = not significant (p > 0.05)
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N
DEVIATION ERROR VALUE VALUE
TIME 1 (PRE) 37 1.76 0.60 0.I0 1 3
TIME 4 (POSg) 37 0.95 0.74 0.12 0 2
WILCOXON T = 6.5 UNTIED N = 22 p <= o.oos
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.
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N
DEVIATION ERROR VALUE VALUE
TIME 1 (PRE) 37 1.54 0.51 0.08 1 2
TIME 4 () 37 i.II 0.31 0.05 1 2
WILCOXON T = 9.5 UNTIED N = 18 p <= 0.005
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses
BLE 9
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N
DEVIATION ERROR VALUE VALUE
TIME 1 (PRE) 37
TIME 4 (POST) 37
0.86 0.35 0.06 0 1
0.41 0.50 0.08 0 1
WILa)XCN T = 22 UNTIED N= 21 p <= 0.005
a) Means, standard deviations, and standard errors are sh(mm for
descriptive purposes only and were not used in the statistical
analyses
BLE I0
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SHPRUI
(0-, 1=POSITIVE)
N
DEVIATION ERRCR VALUE VALUE
TIME 1 (PRE) 37 0.22 0.42 0.07 0 1
TIME 4 (POST) 37 0.05 0.23 0.04 0 1
WILO0XON T = 0 p <= 0.025
a) Means, standard deviations, and standard errors are shown for
descriptive purposes only and were not used in the statistical
analyses.
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N MEAN MINIMUM MAXIMUM MEAN STANII%RD ERRCR
VALUE VALUE DIFFERENCE OF DIFFERENCE
TIME 1 (PRE) 37
TIME 4 (POST) 37
6.32 4 9
5.05 3 9
i .27 0.25
t = 5.02 df=36 p <= 0.O0005,
-89-
VALUE DIFFERENCE OF DIFF
TIME 1 (PRE) 37
TIME 4 (POST) 37
5.65 1 9
4.84 1
t = 4.82 p <= O.00005
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N MEAN MINIMUM MAXI MEAN STANDARD ERROR
VALUE VALUE DIFFERENCE OF DIFFERENCE
TIME 1 (PRE) 37
TIME 4 (P(35T) 37
985 0 4536
1675 80 6525
t = 2.13 df=36 0.040
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N MEAN MINIM[R MAXIMUM MEAN STANDARD ERRCR
VALUE VALUE DIFCE OF DIFFERenCE
TIME i (PRE) 37
TIME 4 () 37
1580 186 5350
904 0 2806
t = 3.35 df=36 p = 0.0019
-92-
(cl[ + cc])
N MEAN MINIMUM MAXI MEAN STANDARD ERRCR
VALUE VALUE DICE OF DICE
TIME 1 (PRE) 37
TIME 4 () 37
70.0 12.5 I00.0
37.5 0 87.3
t = 5.19 df=36 p <= 0.00005
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N MEAN MINI MAXIMUM MEAN STANDARD ERROR
VALUE VALUE DIFFERenCE OF DIFFERENCE
TIME 1 (PRE) 37
TIME 4 () 37
382 0 1680
347 0 1755
35 109
t = 0.32 df=36 p = 0.75 (NSb)
b) NS = not significant (p > 0.05)
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B
N MEAN MINIMUM MAXIMUM MEAN STANDARD ERRCR
VALUE VALUE DIFFERENCE OF DIFFERENCE
TIME 1 (PRE) 37
TIME 4 (POST) 37
125 0 777
138 0 1287
t =-0.25 df=36 p = 0.81 (NSb)
b) NS = not significant (p > 0.05)
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N MEAN MINIM[ MAXIMDM MEAN STANII%RD ERRCR
VALUE VALUE DIFFERENCE OF DIFFERENCE
TIME 1 (PRE) 37
TIME 4 () 37
1626 0 10545
1246 0 5760
380
t = 1.09 df=36 p = 0.28 (b)
b) NS = not significant (p > 0.05)
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FI I. A photograph of a stained crossed-immunoelectrophoresis
gel of gingival fluid from an untreated site of perio-
dontitis. GF=gingival fluid. The precipitates are
labelled.
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FIGURE 2. A photograph of a stained crossed-immunoelectrophoresis
gel of gingival fluid from_ the same site as figure 1
after periodontal therapy. A reduction in C3c can be
observed. GF=gingival fluid. The precipitates are
labelled.
